Top

Published in:

01-09-2019 | Hepatocellular Carcinoma | Editorial

Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma

Authors: Tatsuo Kanda, Osamu Yokosuka, Mitsuhiko Moriyama

Published in: Hepatology International | Issue 5/2019

Excerpt

Hepatocellular carcinoma (HCC) is one of the human cancers with a poor long-term prognosis worldwide. Exosomes could mediate communication between both cancer and non-cancer cells [1]. Recent research demonstrated that proteins, DNAs, and various forms of RNA such as microRNA (miRNA), long noncoding RNA (lncRNA), and messenger RNA (mRNA) transferred by exosomes, all contribute to the development of HCC [1]. …

Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and hepatocellular carcinoma: from bench to bedside. Int J Mol Sci 2019;20:E1406. https://doi.org/10.3390/ijms20061406 (PMID: 30897788) CrossRefPubMed

Yan Y, Lu Y, Mao K, Zhang M, Liu H, Zhou Q, et al. Identification and validation of prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis. Hepatol Int 2019. https://doi.org/10.1007/s12072-019-09962-3 (Epub ahead of print, PMID: 31321712) CrossRefPubMedPubMedCentral

Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, et al. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer. Clin Cancer Res 2019;25:1817–1827. https://doi.org/10.1158/1078-0432.ccr-18-1414 (PMID: 30482779) CrossRefPubMed

Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-catenin signaling in hepatocellular carcinoma. Oncotarget 2017;8:47195–47205. https://doi.org/10.18632/oncotarget.17587 (PMID: 28525379) CrossRefPubMedPubMedCentral

Yang QX, Zhong S, He L, Jia XJ, Tang H, Cheng ST, et al. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett 2019;452:90–102. https://doi.org/10.1016/j.canlet.2019.03.028 (PMID: 30914208) CrossRefPubMed

Mao J, Tian Y, Wang C, Jiang K, Li R, Yao Y, et al. CBX2 Regulates proliferation and apoptosis via the phosphorylation of YAP in hepatocellular carcinoma. J Cancer 2019;10:2706–2719. https://doi.org/10.7150/jca.31845 (PMID: 31258779) CrossRefPubMedPubMedCentral

Smits VAJ, Cabrera E, Freire R, Gillespie DA. Claspin—checkpoint adaptor and DNA replication factor. FEBS J 2019;286:441–455. https://doi.org/10.1111/febs.14594 (PMID: 29931808) CrossRefPubMed

Choi SH, Yang H, Lee SH, Ki JH, Nam DH, Yoo HY. TopBP1 and claspin contribute to the radioresistance of lung cancer brain metastases. Mol Cancer 2014;13:211. https://doi.org/10.1186/1476-4598-13-211 (PMID: 25216549) CrossRefPubMedPubMedCentral

Zou CD, Zhao WM, Wang XN, Li Q, Huang H, Cheng WP, et al. MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget 2016;7:266–278. https://doi.org/10.18632/oncotarget.5689 (PMID: 26497556) CrossRefPubMed

10.

Murata K, Saito A, Katagiri S, Ariizumi S, Nakano M, Yamamoto M. Association of des-γ-carboxy prothrombin production and sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades. J Med Ultrason (2001) 2018;45:223–229. https://doi.org/10.1007/s10396-017-0816-3 (PMID: 28828695) CrossRef

11.

Hamaoka M, Kobayashi T, Tanaka Y, Mashima H, Ohdan H. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: a prospective study. PLoS One 2019;14:e0217586. https://doi.org/10.1371/journal.pone.0217586 (PMID: 31141571) CrossRefPubMedPubMedCentral

Title: Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma
Authors: Tatsuo Kanda
Osamu Yokosuka
Mitsuhiko Moriyama
Publication date: 01-09-2019
Publisher: Springer India
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Hepatology International / Issue 5/2019
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-019-09976-x

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2019

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose–response meta-analysis

Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis

Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis

Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study

An imbalance between stellate cells and γδT cells contributes to hepatocellular carcinoma aggressiveness and recurrence

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage